- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00699504
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
January 13, 2012 updated by: The Medicines Company
A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Tacoma, Washington, United States, 98418
- Charles River Clinical Services NW
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or non pregnant female between 18 years and 45 years of age, inclusive.
- Female subjects of childbearing potential (ie, who have not undergone a hysterectomy, have not had a tubal ligation, have not been postmenopausal for at least 12 consecutive months, or whose partner has not undergone a vasectomy) must commit either to abstain continuously from heterosexual sexual contact or to use two methods of birth control, one of which must be a barrier method (eg, hormonal contraception, latex condom, diaphragm, or cervical cap), beginning at screening and throughout study participation.
- A body mass index (BMI) of 19 kg/m2 to 28 kg/m2, inclusive.
- Agrees to abstain from alcohol consumption for at least 3 days before first dosing with study drug and throughout study participation.
- Agrees to abstain from caffeine and nicotine replacement therapy during the days of study drug administration and serial ECG measurements.
- No clinically significant abnormal findings on the physical examination, ECG, blood pressure, heart rate, medical history, or clinical laboratory tests during screening.
- Serum magnesium and potassium levels within the normal range per the local lab at the time of screening.
- Healthy volunteer as determined by the screening assessments.
- Willing and able to comply with all trial requirements.
- Provide written informed consent before initiation of any study related procedures.
Exclusion Criteria:
- Known or suspected pregnancy.
- Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, tumor, or intracranial aneurysm; recent (<1 month) trauma or major surgery; active bleeding.
- Impaired hemostasis: known International Normalized Ratio (INR) >1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count <100,000/µL).
- Sustained supine systolic blood pressure >140 mmHg or <100 mmHg or a diastolic blood pressure >95 mmHg or <60 mmHg at screening or baseline. Blood pressure may be retested twice in the supine position at intervals of 5 minutes. Blood pressure is considered sustained if either the systolic or the diastolic pressure exceeds the stated limits after three assessments.
- Resting pulse rate of <50 beats per minute (bpm) or >100 bpm.
- Abnormality in the 12 lead ECG that, in the opinion of the investigator, increases the risk of participating in the study, such as a corrected QT interval (QTcB or QTcF) >450 milliseconds. The following conduction abnormalities may confound QTc analysis and should be avoided: PR >220 milliseconds, second or third degree atrioventricular (AV) block, intraventricular conduction defect (IVCD) with QRS >120 milliseconds, complete left bundle branch block (LBBB), left anterior fascicular block (LAFB), left posterior fascicular block (LPFB), right bundle branch block (RBBB), or Wolff Parkinson White syndrome (WPW) (WPW defined as PR >120 milliseconds, P axis from 1 to 90, QRS complex >120 milliseconds, delta wave present).
- Personal history of long QT syndrome, heart failure, or hypokalemia.
- Personal history of unexplained syncope.
- Immediate-family history of long QT syndrome.
- Family history of sudden death.
- Concurrent medical conditions, therapy, or medications that affect the ECG, especially prolongation of the QT/QTc interval.
- Use of prescription or over the counter (such as pseudoephedrine containing cold medicines) medication, including herbal remedies and health supplements, known to prolong the QT/QTc interval within 14 days prior to start of the study and throughout study participation.
- Intention to use prescription (other than thyroid hormone replacement if the dose and regimen of such replacement therapy has been stable for at least 4 weeks prior to screening and is expected to remain stable during study participation or hormonal contraception) or over the counter medication, including herbal remedies and health supplements, within 14 days before the initial dose of study drug and throughout study participation. If this situation arises, inclusion of an otherwise suitable volunteer may be at the discretion of the investigator in discussion with the Sponsor.
- Current smokers or subjects who have discontinued smoking fewer than 6 months prior to study entry.
- Donation of any blood or plasma in the last month, or donation of >400 mL of blood within the 3 months preceding study drug administration.
- Clinically significant abnormalities in clinical laboratory test results.
- Positive virology screen for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
- Positive urine test for drugs of abuse or alcohol.
- Clinically significant disease or condition affecting a major organ system, including, but not limited to, gastrointestinal, renal, hepatic, bronchopulmonary, neurological, metabolic or cardiovascular disease.
- Allergy, hypersensitivity, or contraindication to quinolone antibiotics, cangrelor, or any of their excipients.
- History of multiple adverse drug allergies of any origin.
- Deemed by the investigator, for any reason, to be inappropriate for this study, including subjects who are unable to communicate or to cooperate with the investigator.
- Treatment with other investigational agents or devices within the 30 days preceding randomization, planned use of other investigational drugs or devices during study participation, or previous enrollment in this trial.
- Inability to give informed consent or high likelihood of being unable to complete the necessary confinement.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lead in Phase
Supratherapeutic dose of cangrelor
|
IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs.
Oral placebo capsule
60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs.
Oral placebo capsule
|
Experimental: A
therapeutic dose cangrelor treatment
|
IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs.
Oral placebo capsule
60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs.
Oral placebo capsule
|
Experimental: B
supratherapeutic dose cangrelor treatment
|
IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs.
Oral placebo capsule
60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs.
Oral placebo capsule
|
Active Comparator: C
active comparator treatment
|
400 mg orally.
Placebo IV bolus and infusion.
|
Placebo Comparator: D
placebo treatment
|
placebo IV and oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in placebo adjusted QTc with the individual correction method (QTcI) following cangrelor administration.
Time Frame: Baseline to treatment
|
Baseline to treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentrations of study drug and metabolite
Time Frame: Baseline to treatment
|
Baseline to treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
November 1, 2008
Study Completion (Actual)
November 1, 2008
Study Registration Dates
First Submitted
June 13, 2008
First Submitted That Met QC Criteria
June 17, 2008
First Posted (Estimate)
June 18, 2008
Study Record Updates
Last Update Posted (Estimate)
January 18, 2012
Last Update Submitted That Met QC Criteria
January 13, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Moxifloxacin
- Cangrelor
Other Study ID Numbers
- TMC CAN 08 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on cangrelor
-
Attikon HospitalAHEPA University Hospital; University Hospital, AlexandroupolisCompleted
-
The Medicines CompanyCompleted
-
The Medicines CompanyCompleted
-
Federico II UniversityRecruitingCoronary Artery DiseaseItaly
-
University Hospital, CaenTerumo Medical CorporationCompletedST-elevation Myocardial InfarctionFrance
-
The Medicines CompanyCompletedAtherosclerosis | Acute Coronary Syndrome | Percutaneous Coronary InterventionUnited States
-
The Medicines CompanyCompletedAcute Coronary Syndrome (ACS)United States
-
University Medical Centre LjubljanaChiesi Slovenija, d.o.o.CompletedAcute Coronary Syndrome | Out-Of-Hospital Cardiac ArrestSlovenia
-
Ospedale Santa Croce-Carle CuneoUnknownPlatelet Aggregation Inhibitors
-
University of AarhusUnknownMyocardial Infarction | Acute Coronary Syndrome | STEMI - ST Elevation Myocardial InfarctionDenmark